A trial testing different combinations of Nivolumab, Ipilimumab, and OX40 (CD134) agonist in advanced solid tumors, mainly NSCLC and bladder cancers, [100] did not show improved results as compared to Nivolumab combined to Ipilimumab. This evidence concerns the gene TNFRSF4 and urinary bladder cancer.